◆英語タイトル:Synergy Pharmaceuticals Inc - Strategic SWOT Analysis Review
◆商品コード:SWOT20MY2153
◆発行会社(調査会社):
GlobalData
◆発行日:2019年12月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Synergy Pharmaceuticals Inc – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
Synergy Pharmaceuticals Inc (Synergy Pharma) is a biopharmaceutical company that develops and commercializes new treatments for gastrointestinal (GI) diseases. The company pioneered its R&D efforts to develop its proprietary uroguanylin-based GI platform. It is also developing analogs of uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company’s portfolio includes Trulance (plecanatide), which is structurally identical to uroguanylin, for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Synergy Pharma’s pipeline includes dolcanatide (SP-333), an investigational candidate under evaluation for the treatment of OIC and UC. Synergy Pharma is headquartered in New York, the US.
Synergy Pharmaceuticals Inc Key Recent Developments
Mar 01,2019: Synergy Pharmaceuticals receives court approval for the sale of its assets to Bausch Health
Jan 08,2019: Sure Med Compliance partners with Synergy Laboratories to advance the fight against opioid abuse
Dec 14,2018: Bausch Health makes $200m bid for bankrupt Synergy Pharmaceuticals
Nov 08,2018: Synergy Pharmaceuticals reports third quarter 2018 financial results and business update
Oct 31,2018: Synergy Pharmaceuticals names Dr. Melvin K. Spigelman Chairman
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Synergy Pharmaceuticals Inc – Key Facts
Synergy Pharmaceuticals Inc – Key Employees
Synergy Pharmaceuticals Inc – Key Employee Biographies
Synergy Pharmaceuticals Inc – Major Products and Services
Synergy Pharmaceuticals Inc – History
Synergy Pharmaceuticals Inc – Company Statement
Synergy Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Synergy Pharmaceuticals Inc – Business Description
R&D Overview
Synergy Pharmaceuticals Inc – Corporate Strategy
Synergy Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Synergy Pharmaceuticals Inc – Strengths
Synergy Pharmaceuticals Inc – Weaknesses
Synergy Pharmaceuticals Inc – Opportunities
Synergy Pharmaceuticals Inc – Threats
Synergy Pharmaceuticals Inc – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Synergy Pharmaceuticals Inc, Recent Deals Summary
Section 4 – Company’s Recent Developments
Mar 01, 2019: Synergy Pharmaceuticals receives court approval for the sale of its assets to Bausch Health
Jan 08, 2019: Sure Med Compliance partners with Synergy Laboratories to advance the fight against opioid abuse
Dec 14, 2018: Bausch Health makes $200m bid for bankrupt Synergy Pharmaceuticals
Nov 08, 2018: Synergy Pharmaceuticals reports third quarter 2018 financial results and business update
Oct 31, 2018: Synergy Pharmaceuticals names Dr. Melvin K. Spigelman Chairman
Aug 07, 2018: Synergy Pharmaceuticals reports second quarter 2018 financial results and business update
May 10, 2018: Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update
Mar 01, 2018: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Synergy Pharmaceuticals Inc, Key Facts
Synergy Pharmaceuticals Inc, Key Employees
Synergy Pharmaceuticals Inc, Key Employee Biographies
Synergy Pharmaceuticals Inc, Major Products and Services
Synergy Pharmaceuticals Inc, History
Synergy Pharmaceuticals Inc, Subsidiaries
Synergy Pharmaceuticals Inc, Key Competitors
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Synergy Pharmaceuticals Inc, Recent Deals Summary
List of Figures
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019